Sunday, February 25, 2018

Intas Pharmaceuticals Limited, India’s one of the fastest growing pharmaceutical company, is pleased to announce a big step which will bring relief to large number of cancer patients in the country for whom the drug – Bevacizumab was out of reach till today. Intas’s bevacizumab therapy is priced at Rs. 39995 for the dose strength of 400mg variant which makes it 60% less than the currently available options.

Every year over 7 lakh patients die du
e to various types of cancer in India. At Intas we believe in the philosophy of “Patient First”. Hence, in order to relieve the patients from the financial burden associated with the treatment, thiscost effective measure is implemented by the organisation. The step is entirely focussed in making the drug treatment accessible to cancer patients in India thus, providing them with a beacon of hope in their fight against the disease.

Bevacizumab is a drug which works by slowing the growth of new blood vessels and is used in treating multiple-cancers like colorectal cancer, ovarian cancer, cervical cancer, lung cancer and recurrent glioblastoma (a type of brain tumour). The drug has been available in India since 2004 but the cost has been so prohibitive that as per eminent clinicians of the country they have been able to give this drug to very few eligible patients.